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Abstract
Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts
in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test,
denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship
between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC.
Patients and methods: A total of 125 patients were prospectively enrolled from a university
head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two
control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total
of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H
radioimmunoassay.
Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/
mL, and 12.8 ng/mL, respectively (p = 0.0001).
Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with
HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response
to treatment in HNSCC patients.
Background
Effective therapy for head and neck squamous cell carci-
noma (HNSCC), which constitutes approximately 95% of
head and neck malignancies, is dependent upon early
diagnosis and intervention. Despite the obvious advan-
tage to earlier diagnosis of head and neck malignancies,
no strategy has proven to effectively detect these tumors at
early stages. Most head and neck neoplasms are detected
when the patient has become symptomatic from the
effects of the primary disease or when lymphatic metas-
tases are palpable. These tumors are infrequently found
incidentally on physical exam, and in these cases are often
discovered at an earlier stage. Stage of disease at time of
diagnosis is the primary metric used for determination of
therapy and prognostication of life expectancy [1]. As
tumor stage advances, the morbidity of surgical resection
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involvement of vital structures. Organ-sparing approaches
to head and neck malignancies have been developed in an
attempt to treat advanced stage lesions while avoiding
conventional surgical morbidities. They have, however,
not produced universally superior results to surgery both
in terms of local-regional control and function.
Surveillance in the post-treatment head and neck cancer
patients has traditionally centered on regular physical
examination [2,3]. Office flexible fiberoptic exams of
these patients have provided an excellent means of diag-
nosis for early mucosal recurrences, but are dependent
upon the patient's compliance with regular follow-up and
often cannot detect submucosal recurrence. Anatomic
imaging is used as an adjunct to regular physical exam
when recurrence is suspected, when findings are sugges-
tive of cervical lymphatic involvement, or when a patient's
symptoms are out of proportion or unexplained by phys-
ical exam findings. Imaging of anatomic structures is com-
plicated by alterations in anatomy due to previous surgery
or irradiation. Furthermore, despite many promising early
reports, no tumor marker has yet been adopted for clinical
use which shows high specificity or sensitivity for primary
or recurrent HNSCC [4-8].
Metallopanstimulin-1 (MPS-1) was identified, cloned and
characterized in the laboratory of Dr. Fernandez-Pol from
a cDNA library constructed from a human mammary car-
cinoma cell line (MDA-468) that was stimulated by the
growth factors TGF-β1 and EGF in the presence of
cyclohexamide [9]. MPS-1, a multifunctional S27 ribos-
omal protein, is an 84 amino acid 9.5 kD ribosomal sub-
unit, "zinc finger" protein that is present in all tissues and
expressed in large quantities in a wide spectrum of prolif-
erating tissues and oncogenic processes [10-16]. When
MPS-1 is over-expressed, it is either secreted or passively
released down a concentration gradient into the extra-cel-
lular space.
Conventionally, ribosomal proteins are thought to be
confined in their function to intracellular protein synthe-
sis. Many recent reports have drawn attention to "extrari-
bosomal functions" of ribosomal proteins [17-20].
Moreover, these extraribosomal functions have been
observed in relation to oncogenesis in various models
[21,22]. The zinc finger motif of MPS-1 and other ribos-
omal proteins may allow binding to nucleic acids which
may result in interference with transcription and transla-
tion [10,17,18]. Practical applications of this include: 1)
DNA repair, 2) gene suppression, 3) cell-cycle control, or
4) control of oncogenesis. Another related ribosomal pro-
tein, S27a, is ubiquitinilated and over expressed in human
colon cancer. Like MPS-1, it is involved in cell-cycle con-
trol and DNA replication [23].
The physiology of MPS-1 expression and our initial expe-
rience with this protein in HNSCC has led us to conclude
that MPS-1 and MPS-1-like proteins may be useful mark-
ers in the effort to screen for and analyze the extent of
HNSCC [24]. The purpose of this study was to use an
empirical MPS-H test, which measures both MPS-1 and
MPS-1-like proteins, to 1) compare average MPS-H levels
between HNSCC patients and normal controls and 2) to
illustrate how the MPS-H test may be useful for surveil-
lance and evaluating response to treatment for HNSCC.
Patients and methods
Patients
A total of 125 volunteers with newly diagnosed HNSCC
were prospectively enrolled from a university head and
neck oncology clinic. Serum collection consisted of a pre-
treatment specimen followed by collections every six
weeks during the first year and quarterly during the sec-
ond year. At the time of specimen collection, presence of
HNSCC was judged by all available data including: phys-
ical examination (that included an office endoscopy when
indicated), biopsy, and radiology [computerized tomog-
raphy (CT), magnetic resonance imaging (MRI), or posi-
tron emission tomography (PET)]. A clinical assessment
was rendered based on all available data as "no evidence
of disease (NED)", "alive with disease", or an indetermi-
nate status. Serum MPS-H levels in these patients (N =
709) were compared to two control groups. The first con-
trol group was comprised of 25 normal, healthy, non-
smoking volunteers. The second control group included
64 actively smoking volunteers who were screened for
HNSCC and were found to be free of disease during the
1999 Yul Brynner Head and Neck Screening day in St.
Louis, Missouri. A total of 821 serum samples collected
over a twenty-four month period were analyzed by the
MPS-H radioimmuno assay (follow-up days, mean: 217,
median: 166.). All patients gave informed consent under
an IRB-approved protocol.
MPS-H Serum Assay
Technical details for the preparation of reagents for MPS-
H antigen determinations, RIA procedure, and patient
sample preparation are published elsewhere [9,10]. Each
serum sample was run in duplicate by a single technician
who was blinded to specimen identity. The targets of this
assay are the MPS-N-terminus of both MPS-1 and MPS-1-
like proteins. These proteins are activated or released from
the precursor or carrier proteins by heat-denaturing of the
serum under controlled conditions. The resulting proteins
are collectively designated as MPS-H. Immunoreactive
substances detected by the MPS-H test do not reflect the
true levels of authentic immunoreactive MPS-1/S27 ribos-
omal protein in the circulation under non-denatured
conditions.Page 2 of 9
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Average MPS-H levels were compared between HNSCC
patients and the two control groups and across American
Joint Committee on Cancer (AJCC) stages and subsites
using analysis of variance (ANOVA). Based on the results
from the clinical assessment we computed the receiver
operating characteristic (ROC) curve for MPS-H. The ROC
curve plots the trade-off between sensitivity and specificity
for a range of threshold values for defining a positive
result. All ANOVA and contingency table analysis were
performed using SAS (version 8.1, Cary, NC) statistical
software. ROC curve analysis was performed using R soft-
ware, an open source implementation of the S language
(version 1.4.1, http://www.r-project.org). Statistical sig-
nificance was defined as p < 0.05.
Results
Of the 125 HNSCC patients studied, 90 were male (Table
1). Table 2 presents the distribution of stage and site of the
primary tumor. Most patients presented in stage III
(24.0%) or IV (50.4%) with primary tumors of the oral
cavity (26.4%) and larynx (37.6%).
MPS-H levels in this group were compared to a control
group of healthy volunteers and to a control group who
volunteered for screening for head and neck cancer (Fig-
ure 1). Mean MPS-H was 10.2 ng/mL for the healthy con-
trol group, and 12.8 ng/mL for the smoking control
group. Mean MPS-H for the HNSCC group was 41.5 ng/
mL, which was significantly higher than both control
groups (p < 0.0001). Furthermore, Figure 2 illustrates that
among HNSCC patients, those who were successfully
treated and clinically free of disease had consistently
lower MPS-H levels over time than patients living with
active head and neck cancer.
We next computed the receiver operating characteristic
(ROC) curve for the MPS-H levels. Figure 3 shows that the
area under the ROC curve (0.73; 95% CI: 0.71–0.75; p =
0.001), is significantly different from 0.5, which suggests
that there is moderate diagnostic accuracy associated with
MPS-H. Analysis of MPS-H levels as a function of AJCC
stage or head and neck sub site were performed and were
not significant. Larger numbers of earlier stage (I and II)
tumors and greater numbers among the various sub sites
might result in significance.
We have observed several instances where elevated MPS-
H levels in patients presenting with head and neck
neoplasms dropped to normal levels following successful
Table 1: Demographic and treatment characteristics of cases
Gender Radiation/Chemo Surgery Total
Female N 7 28 35
% 5.6% 22.4%
Male N 19 71 90
% 15.2% 56.8%
Total N 26 99 125
% 20.8% 79.2% 100.0%
Table 2: Summary of primary tumor stage and location.
Primary Stage
Tumor Site I II III IV Total Percent
Hypopharynx 0 1 0 1 2 1.6%
Larynx 7 4 18 18 47 37.6%
Nasopharynx 0 0 0 4 4 3.2%
Neck 0 1 1 3 5 4.0%
Oral Cavity 5 8 4 16 33 26.4%
Oropharynx 0 0 2 18 20 16.0%
Parotid 0 0 2 0 2 1.6%
Skin 4 2 3 3 12 9.6%
Total 16 16 30 63 125
Percent 12.8% 12.8% 24.0% 50.4% 100.0%Page 3 of 9
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tions or increases in MPS-H levels in patients with failure
to respond to therapy or with recurrence of tumor respec-
tively. Several cases of patients presented in Figures 4, 5, 6
illustrate these phenomenons. Patient 1 (Figure 4) was a
female with a T4N0M0 SCC of the floor of mouth with pos-
itive tumor margins on the cut edge of the mandible, hav-
ing failed a recent limited surgery by another surgeon. Her
presenting MPS-H value was borderline positive when she
had little clinical disease [1 on the x axis] and rose imme-
diately postoperatively. A transient rise after surgical abla-
tion or induction chemotherapy is a documented
phenomenon observed with numerous tumor markers
(personal communication J.A. Fernandez-Pol). The eleva-
tion likely results from a large initial disruption of cells
within the tumor resulting in a dumping of intracellular
MPS-1 into the circulation. This usually returns to base-
line in 4 to 6 weeks if the tumor is successfully treated. The
patient was clinically NED in the immediate postopera-
tive period and during radiation treatment. Approxi-
mately 6 months post operatively, the patient developed
a neck mass and by the next visit skin metastasis were
seen. On last follow-up, the patient had progression of
skin and neck metastasis at which time she decided to pur-
sue hospice care. She expired 6 weeks later.
Patient 2 (Figure 5) is a male who was diagnosed with a
T4N2cM0 SCC of the larynx, which required total laryngec-
tomy, bilateral neck dissections, and postoperative radia-
tion therapy. The patient joined this study 3 months
following his surgery, while clinically NED, and has
remained free of clinical recurrence for 24 months. The
Mean serum MPS-H level for patients with SCC (n = 125, all stages and sites within the head and neck), healthy control group (n = 51) and actively smoki g volunteers who we e cre ned for HNSCC (N = 64)Fig re 1
Mean serum MPS-H level for patients with SCC (n = 125, all 
stages and sites within the head and neck), healthy control 
group (n = 51) and actively smoking volunteers who were 
screened for HNSCC (N = 64). Mean of SCC group is 41.5 
ng/mL, mean of healthy control group is 10.2 ng/mL, and 
mean of screening controls is 12.8 ng/mL (p < 0.0001). Error 
bars denote 1 standard deviation.
Serial MPS-H levels in HNSCC patients treated and without clin cal disease (No Disease) and patients wi h unresectable dise se or rec i ing palli tive therapy with persistent linical (Alive with isease)F gur  2
Serial MPS-H levels in HNSCC patients treated and without 
clinical disease (No Disease) and patients with unresectable 
disease or receiving palliative therapy with persistent clinical 
disease (Alive with Disease). Error bars denote 1 standard 
deviation and vary widely in the AWD group due to its small 
size and patient attrition over time from death.
Receiver operating characteristic (ROC) curve for MPS-H testFigure 3
Receiver operating characteristic (ROC) curve for MPS-H 
test. Area under the curve is 0.73 (CI95: 0.69 – 0.76, p = 
0.001)Page 4 of 9
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following his surgery that were all negative for recurrent
disease or metastasis. His persistently low MPS-H levels
over time (range from 7.7–19.2 ng/mL), was suggestive of
ongoing disease-free status.
Patient 3 (Figure 6) was a female who presented with a
T4N0M0 SCC of the hypopharynx. She was severely mal-
nourished with multiple medical problems and thought
to be a poor surgical candidate. She decided to pursue
induction chemotherapy (Carboplatin and Taxol) to be
followed by radiation therapy. She underwent three
rounds of chemotherapy at 21-day intervals and had a
50% decrease in her tumor size as judged by office endos-
copy. She suffered severe GI problems during her therapy,
opted not to continue on to radiation, and enrolled in
hospice care. The patient did not present for additional
follow-up after entering hospice and died three months
later. This case illustrates the potential utility of MPS-H as
a marker for tumor response to chemotherapy and/or
irradiation.
Discussion
Histological examination of the tumor, surgical margins,
and cervical nodes are the current means of determining
extent of disease. When surgical extirpation is not
undertaken, staging is performed based on a radiological
assessment, biopsy, and physical examination. These
methods are used either to determine adequacy of resec-
tion and the need for adjuvant therapy or to select an
alternative primary (non-surgical) therapy, respectively.
Limitations of the histologic method include microscopic
disease that escapes diagnosis due to a small number of
malignant cells, subtle histological changes not classified
as cancer, previous treatment effect upon tissues, or path-
ologic sampling error. CT and physical examination both
suffer from modest sensitivity and specificity in detecting
many early head and neck neoplasms. As a result, local
Patient without evidence of disease from surgery through radiation therapy (draws 1–5)Figure 4
Patient without evidence of disease from surgery through radiation therapy (draws 1–5). The patient suffered a recurrence of 
clinical disease following radiation therapy (draws 6–8), which progressed until death.Page 5 of 9
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both surgical and non-surgical treatments of head and
neck cancer. This may be due to an underestimation of the
tumor burden. This may also be explained by the current
diagnostic emphasis upon analysis of structure (micro-
scopic) or anatomic extent of disease, both of which are
imperfect, rather than its biologic activity as might be
measured by a tumor marker or a functional scanning
technique such as FDG-PET.
The MPS-H test has been used in conjunction with con-
ventional tumor-specific markers to improve sensitivity
and specificity of tumor serodiagnosis [12]. Of all
malignancies in which MPS-H has been studied to date,
epithelial malignancies possess no alternative tumor
markers in clinical use that have been effective for diagno-
sis or surveillance [4-8,23]. This observation in conjunc-
tion with the current dependence on anatomic evaluation
for diagnosis of epithelial malignancies has led us to
preliminary investigations of the utility of MPS-H sero-
logic diagnosis for the detection of head and neck epithe-
lial neoplasms.
Control groups of healthy volunteers and those with sys-
temic, non-malignant diseases have been studied using
the MPS-H test. Statistical analysis has revealed that those
without malignancy have MPS-H serum levels less than
10 ng/mL, those with malignancy have levels greater than
20 ng/mL, and those with bony metastasis have levels in
excess of 100 ng/mL [12]. Additionally, MPS-H levels
have been documented to decline with successful
treatment of malignant disease whereas non-responders
to therapy persisted with high levels of MPS-H [12].
Serum samples from prostate carcinoma patients with
high levels of MPS-H (>500 ng/mL) have demonstrated
the authentic 9.4 kDa MPS-1 protein, at least one protein
with sequence homology to the N-terminus of MPS-1,
Patient followed for 24 months without evidence of recurrence on physical exam, endoscopy, or FDG-PETFigure 5
Patient followed for 24 months without evidence of recurrence on physical exam, endoscopy, or FDG-PET.Page 6 of 9
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protein.
More accurate detection of recurrent SCC of the head and
neck by the MPS-H test may provide a new way to
improve survival. Physical exam, conventional imaging,
and biopsy are the current gold standard to determine
recurrence. Currently, FDG-PET is the most promising
way to assess early tumor recurrence of the head and neck
but is quite expensive [25,26]. Its sensitivity and specifi-
city have been reported to be approximately 90% [25,26].
No standard serum tumor marker is routinely used for
head and neck cancer surveillance, which limits alterna-
tives to conventional exams or frequent FDG-PET imaging
[4-8,25].
In the present study we compared FGD-PET to MPS-H lev-
els in head and neck cancer patients. FDG-PET
interpretation and MPS-H level determination were
performed independently and blinded from the results of
the other test. FDG-PET positive scans were not all con-
firmed by biopsy in our study. A statistically significant
correlation was noted between FDG-PET positive cases
and high MPS-H serum levels in head and neck cancer
patients. MPS-H and FDG-PET agreed in 103 out of 183
cases. In 12 cases MPS-H was elevated but no cancer was
found by FDG-PET, suggesting that the patients may have
had an early recurrence detectable by MPS-H but not yet
by FDG-PET. The 68 FDG-PET positive cases that show
low MPS-H levels suggest that some tumors were unable
to produce high levels of MPS-H, perhaps due to previous
chemotherapy, or that some results represent false posi-
tive PET scans. Further study with larger patient groups is
Patient with unresectable tumorFigure 6
Patient with unresectable tumor. Note MPS-H level response to chemotherapy. Patient subsequently expired after refusing fur-
ther therapy.Page 7 of 9
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the correlation between FDG-PET and MPS-H.
Shortcomings of this study include a limited time span, a
large proportion of advanced stage cancers, limited
controls (both size, smoking status, and age/gender
match), and ability to define an absolute cut off value for
normal vs. abnormal. We recognize that other factors such
as age and other malignancies may effect MPS levels.
Future studies will attempt to address and/or control for
these issues.
Considering the data presented in this paper, which agrees
with previous results with other tumor types, and the
compelling need to expedite the early diagnosis of pri-
mary and recurrent epithelial malignancies of the head
and neck, we are further evaluating the MPS-H tests as a
tool for diagnosis in a larger group of HNSCC patients.
Additionally, we are working to improve the diagnostic
technology used to detect MPS-H [27-29]. Since there is a
reasonable correlation between detection of MPS-H in the
sera and FDG-PET positivity for SSC, these results raises
the potential of the MPS-H test for becoming a test for
HNSCC, followed by selective confirmatory FDG-PET
imaging. These preliminary results will be verified in a
larger population. The role for using MPS-H as a general
screening tool among at-risk populations without the
diagnosis of HNSCC is also currently being evaluated.
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